Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents findings from a biomarker analyses from the Phase III CheckMate 649 trial (NCT02872116) of first-line nivolumab and chemotherapy or ipilimumab for patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC). Patients with high inflammation, levels of T-regulatory cells (Treg) and tumor proliferation tended to have better outcomes. Low angiogenesis and fibroblast levels were additionally associated with favorable results. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.